CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wex Pharmaceuticals Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wex Pharmaceuticals Inc.
Suite 1601 - 700 West Pender Street
Phone: 604-683-8880p:604-683-8880 Vancouver, BC  V6C 1G8  Canada Ticker: WXIWXI

This company was Merged or Acquired on 5/5/2011.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
WEX Pharmaceuticals Inc. is engaged in the discovery, development, manufacture and commercialization of drug products treat pain management. The Company’s platform is tetrodotoxin (TTX), a selective sodium channel blocker. Its product based on TTX is in Phase III clinical development for the treatment of cancer-related pain. As of December 31, 2010, it has completed five clinical trials with TTX, with more than 200 patients treated. The Company products include TTX for cancer-related pain, TTX for chemotherapy-induced neuropathic pain and Scientific Publications. The Company’s TEC-006 is a clinical trial for the treatment of moderate to severe inadequately controlled cancer-related pain. Its TTX-CINP-201 is a clinical trial for the treatment of moderate to severe neuropathic pain caused by chemotherapy in patients with cancer. The Company is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (CKLS).

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201012/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board AlanYu 10/17/2007 7/15/2007
President, Chief Executive Officer BinHuang 11/20/2007 11/20/2007
Chief Financial Officer, Vice President - Finance and Administration KwongChoo 7/1/2008 12/17/2007
6 additional Officers and Directors records available in full report.

Business Names
Business Name
INTERNATIONAL WEX TECHNOLOGIES INC.
International Wex Technologies, Inc.
IWT Bio Inc. (“IWT”)
Nanning Maple Leaf Pharmaceutical Co. Ltd.
WEX Medical Limited
WXI

General Information
Number of Employees: 71 (As of 3/31/2006)
Outstanding Shares: 442,766,963 (As of 4/4/2011)
Stock Exchange: TSE
Fax Number: 604-683-8868
Email Address: wex@wexpharma.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023